PROGRAM OVERVIEW This education is focused on educating the multidisciplinary team caring for patients at risk for secondary stroke, supporting the unique roles of hematologists, neurologists, and cardiologists in the era of FXI/FXIa inhibitor therapies. LEARNING OBJECTIVES Upon completion of this activity, learners should be able to: Articulate the scientific basis for combining Factor XIa inhibition with antiplatelet therapy in the context of secondary stroke prevention. Distinguish how Factor XIa inhibition selectively disrupts pathological thrombosis while preserving hemostasis compared with conventional antithrombotic approaches. Recognize key efficacy and safety outcomes from Phase III clinical trials of Factor XIa inhibitors in secondary stroke prevention. Assess the generalizability of Factor XIa inhibitors clinical trial populations to patients encountered in routine clinical practice. Envision the evolving role of hematologists in Factor XIa inhibitors in secondary stroke prevention algorithms. Evaluate multidisciplinary best practices that optimize secondary stroke prevention outcomes and support effective cross-specialty communication among hematology, stroke neurology, and cardiology.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- Chandler Building
Pricing
CME included with membership
| Non-member – Pharmacy SIG Journal Club (per session) | $35 |
| Member – Pharmacy SIG Journal Club (per session) | Free |
| Non-member – 2025 Fundamentals of HCT eBook | $400 |
| Member – 2025 Fundamentals of HCT eBook | $200 |
Collected from the provider’s public pages · source
Specialties served/covered
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Diagnostic Radiology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Hematology
- Medical Oncology
- Metabolic & Bariatric Surgery
- Nephrology
- Neurology
- Neuromuscular Medicine
- Nuclear Medicine
- Ophthalmology
- Pediatric Neurology
- Pulmonary Disease
- Rheumatology
- Transplant Surgery
- Urological Oncology
- Vascular Neurology
- Cardio-Vascular
- Cross-Specialty
- GI & Liver
- Medical Subspecialties
- Neurology
- Oncology & Hematology
- Pathology & Lab
- Primary care
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
CME access requires membership — $35–400
Free membership available for some groups
See plans on academy.isth.orgListed by the provider
- Case-based learning
- includes Online course / module
- Credit · Up to 1 credit
- Members only
- Commercial Support
-
ReleasedAug 31, 2026
-
Last day to claim creditAug 31, 2027 11 months left
-
International Society on Thrombosis and Haemostasis +1 Emerging Therapies in Thrombosis: Factor XI/XIa Inhibitors: Learning More: FXI/XIa Inhibitor Trials
-
International Society on Thrombosis and Haemostasis +1 Evaluating the potential of factor XI/factor XIa inhibitors to address unmet anticoagulation needs in critical patient populations
-
International Society on Thrombosis and Haemostasis +1 Perspectives: What We Are Learning From FXI/FXIa Inhibitor Trials
